CD73 Protein as a Source of Extracellular Precursors for Sustained NAD+ Biosynthesis in FK866-treated Tumor Cells

Journal of Biological Chemistry

Volumn 288, Issue 36, 2013, Pages 25938-25949

  Grozio, Alessia ^a   Sociali, Giovanna ^a   Sturla, Laura ^a   Caffa, Irene ^b   Soncini, Debora ^b   Salis, Annalisa ^a   Raffaelli, Nadia ^c   De Flora, Antonio ^a   Nencioni, Alessio ^b   Bruzzone, Santina ^a  

^a Center of Excellence for Biomedical Research   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR ACTIVITIES; CANCER MODELS; CLINICAL STUDY; EXTRACELLULAR; TUMOR CELLS;

BIOCHEMISTRY; DISEASES; TUMORS;

BIOSYNTHESIS;

5' NUCLEOTIDASE; CD38 ANTIGEN; DAPORINAD; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE NUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE RIBOSIDE;

ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INHIBITION; EXTRACELLULAR SPACE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE; TUMOR CELL;

CANCER THERAPY; CD73; CELL DEATH; NAD; NAD BIOSYNTHESIS; NICOTINAMIDE; NICOTINAMIDE MONONUCLEOTIDE; NICOTINAMIDE RIBOSIDE;

5'-NUCLEOTIDASE; ACRYLAMIDES; ANTIGENS, CD38; CELL DEATH; CELL LINE, TUMOR; CYTOKINES; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GPI-LINKED PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; NAD; NEOPLASM PROTEINS; NEOPLASMS; NICOTINAMIDE MONONUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES;

EID: 84883738070     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.470435     Document Type: Article

References (60)

1. Lee, H. C. (2012) Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization. J. Biol. Chem. 287, 31633-31640
2. Lee, H. C. (2012) The cyclic ADP-ribose/NAADP/CD38-signaling pathway. Past and present. Messenger 1, 16-33
3. Belenky, P., Bogan, K. L., and Brenner, C. (2007) NAD metabolism in health and disease. Trends Biochem. Sci. 32, 12-19
4. Koch-Nolte, F., Haag, F., Guse, A. H., Lund, F., and Ziegler, M. (2009) Emerging roles ofNAD and its metabolites in cell signaling. Sci. Signal. 2, mr1
5. Chiarugi, A., Dölle, C., Felici, R., and Ziegler, M. (2012) TheNADmetabolome. A key determinant of cancer cell biology. Nat. Rev. Cancer 12, 741-752
6. Magni, G., Amici, A., Emanuelli, M., Raffaelli, N., and Ruggieri, S. (1999) Enzymology of NAD synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 73, 135-182, xi
7. Houtkooper, R. H., and Auwerx, J. (2012) Exploring the therapeutic space around NAD. J. Cell Biol. 199, 205-209
8. Rongvaux, A., Shea, R. J., Mulks, M. H., Gigot, D., Urbain, J., Leo, O., and Andris, F. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32, 3225-3234
9. Lau, C., Niere, M., and Ziegler, M. (2009) The NMN/NaMN adenylyltransferase (NMNAT) protein family. Front. Biosci. 14, 410-431
10. Stein, L. R., and Imai, S. (2012) The dynamic regulation of NAD metabolism in mitochondria. Trends Endocrinol. Metab. 23, 420-428
11. Hasmann, M., and Schemainda, I. (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436-7442
12. Bruzzone, S., Fruscione, F., Morando, S., Ferrando, T., Poggi, A., Garuti, A., D'Urso, A., Selmo, M., Benvenuto, F., Cea, M., Zoppoli, G., Moran, E., Soncini, D., Ballestrero, A., Sordat, B., Patrone, F., Mostoslavsky, R., Uccelli, A., and Nencioni, A. (2009) Catastrophic NAD depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 4, e7897
13. Montecucco, F., Bauer, I., Braunersreuther, V., Bruzzone, S., Akhmedov, A., Lüscher, T. F., Speer, T., Poggi, A., Mannino, E., Pelli, G., Galan, K., Bertolotto, M., Lenglet, S., Garuti, A., Montessuit, C., Lerch, R., Pellieux, C., Vuilleumier, N., Dallegri, F., Mage, J., Sebastian, C., Mostoslavsky, R., Gayet-Ageron, A., Patrone, F., Mach, F., and Nencioni, A. (2013) Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid. Redox Signal. 18, 630-641
14. Watson, M., Roulston, A., Belec, L., Billot, X., Marcellus, R., Bedard, D., Bernier, C., Branchaud, S., Chan, H., Dairi, K., Gilbert, K., Goulet, D., Gratton, M. O., Isakau, H., Jang, A., Khadir, A., Koch, E., Lavoie, M., Lawless, M., Nguyen, M., Paquette, D., Turcotte, E., Berger, A., Mitchell, M., Shore, G. C., and Beauparlant, P. (2009) The small molecule GMX1778 is a potent inhibitor of NAD biosynthesis. Strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol. Cell Biol. 29, 5872-5888
15. Hjarnaa, P. J., Jonsson, E., Latini, S., Dhar, S., Larsson, R., Bramm, E., Skov, T., and Binderup, L. (1999) CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res. 59, 5751-5757
16. Fleischer, T. C., Murphy, B. R., Flick, J. S., Terry-Lorenzo, R. T., Gao, Z. H., Davis, T., McKinnon, R., Ostanin, K., Willardsen, J. A., and Boniface, J. J. (2010) Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. Chem. Biol. 17, 659-664
17. Lockman, J. W., Murphy, B. R., Zigar, D. F., Judd, W. R., Slattum, P. M., Gao, Z. H., Ostanin, K., Green, J., McKinnon, R., Terry-Lorenzo, R. T., Fleischer, T. C., Boniface, J. J., Shenderovich, M., Willardsen, J. A. (2010) Analogues of 4-[(7-bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop- 2-ynylamino]-N-(3-pyridy lmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt). J. Med. Chem. 53, 8734-8746
18. Cea, M., Cagnetta, A., Fulciniti, M., Tai, Y. T., Hideshima, T., Chauhan, D., Roccaro, A., Sacco, A., Calimeri, T., Cottini, F., Jakubikova, J., Kong, S. Y., Patrone, F., Nencioni, A., Gobbi, M., Richardson, P., Munshi, N., and Anderson, K. C. (2012) Targeting NAD salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signalregulated kinase (ERK1/2) inhibition. Blood 120, 3519-3529
19. Fuchs, D., Rodriguez, A., Eriksson, S., Christofferson, R., Sundberg, C., and Azarbayjani, F. (2010) Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance. Int. J. Cancer 126, 2773-2789
20. Beauparlant, P., Bedard, D., Bernier, C., Chan, H., Gilbert, K., Goulet, D., Gratton, M. O., Lavoie, M., Roulston, A., Turcotte, E., and Watson, M. (2009) Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anti-cancer drugs 20, 346-354
21. Zoppoli, G., Cea, M., Soncini, D., Fruscione, F., Rudner, J., Moran, E., Caffa, I., Bedognetti, D., Motta, G., Ghio, R., Ferrando, F., Ballestrero, A., Parodi, S., Belka, C., Patrone, F., Bruzzone, S., and Nencioni, A. (2010) Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp. Hematol. 38, 979-988
22. Pogrebniak, A., Schemainda, I., Azzam, K., Pelka-Fleischer, R., Nüssler, V., and Hasmann, M. (2006) Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur. J. Med. Res. 11, 313-321
23. Cea, M., Soncini, D., Fruscione, F., Raffaghello, L., Garuti, A., Emionite, L., Moran, E., Magnone, M., Zoppoli, G., Reverberi, D., Caffa, I., Salis, A., Cagnetta, A., Bergamaschi, M., Casciaro, S., Pierri, I., Damonte, G., Ansaldi, F., Gobbi, M., Pistoia, V., Ballestrero, A., Patrone, F., Bruzzone, S., and Nencioni, A. (2011) Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PloS One 6, e22739
24. Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., and Ashworth, A. (2012) Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells. EMBO Mol. Med. 4, 1087-1096
25. Holen, K., Saltz, L. B., Hollywood, E., Burk, K., and Hanauske, A. R. (2008) The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs 26, 45-51
26. von Heideman, A., Berglund, A., Larsson, R., and Nygren, P. (2010) Safety and efficacy of NAD depleting cancer drugs. Results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol. 65, 1165-1172
27. Nikiforov, A., Dölle, C., Niere, M., and Ziegler, M. (2011) Pathways and subcellular compartmentation of NAD biosynthesis in human cells. From entry of extracellular precursors to mitochondrialNADgeneration. J. Biol. Chem. 286, 21767-21778
28. Wang, P., Xu, T. Y., Guan, Y. F., Tian, W. W., Viollet, B., Rui, Y. C., Zhai, Q. W., Su, D. F., and Miao, C. Y. (2011) Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann. Neurol. 69, 360-374
29. De Flora, A., Zocchi, E., Guida, L., Franco, L., and Bruzzone, S. (2004) Autocrine and paracrine calcium signaling by the CD38/NAD/cyclic ADP-ribose system. Ann. N.Y. Acad. Sci. 1028, 176-191
30. Billington, R. A., Bruzzone, S., De Flora, A., Genazzani, A. A., Koch-Nolte, F., Ziegler, M., and Zocchi, E. (2006) Emerging functions of extracellular pyridine nucleotides. Mol. Med. 12, 324-327
31. Bruzzone, S., Guida, L., Sturla, L., Usai, C., Zocchi, E., and De Flora, A. (2012) Subcellular and intercellular traffic of NAD, NAD precursors and NAD-derived signal metabolites and second messengers. Old and new topological paradoxes. Messenger 1, 34-52
32. Bieganowski, P., and Brenner, C. (2004) Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD in fungi and humans. Cell 117, 495-502
33. Yoshino, J., Mills, K. F., Yoon, M. J., and Imai, S. (2011) Nicotinamide mononucleotide, a key NAD intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528-536
34. Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., Milbrandt, J., Kiess, W., and Imai, S. (2007) Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6, 363-375
35. Hara, N., Yamada, K., Shibata, T., Osago, H., and Tsuchiya, M. (2011) Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS One 6, e22781
36. Imai, S. (2009) The NAD world. A new systemic regulatory network for metabolism and aging. Sirt1, systemicNADbiosynthesis, and their importance. Cell Biochem. Biophys. 53, 65-74
37. Wang, P., Xu, T. Y., Guan, Y. F., Su, D. F., Fan, G. R., and Miao, C. Y. (2009) Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor. Role of nicotinamide mononucleotide. Cardiovasc. Res. 81, 370-380
38. Sauve, A. A., Munshi, C., Lee, H. C., and Schramm, V. L. (1998) The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries. Biochemistry 37, 13239-13249
39. Bogan, K. L., and Brenner, C. (2008) Nicotinic acid, nicotinamide, and nicotinamide riboside. A molecular evaluation of NAD precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115-130
40. Garavaglia, S., Bruzzone, S., Cassani, C., Canella, L., Allegrone, G., Sturla, L., Mannino, E., Millo, E., De Flora, A., and Rizzi, M. (2012) The highresolution crystal structure of periplasmic Haemophilus influenzae NAD nucleotidase reveals a novel enzymatic function of human CD73 related to NAD metabolism. Biochem. J. 441, 131-141
41. Wellings, D. A., and Atherton, E. (1997) Standard Fmoc protocols. Methods Enzymol. 289, 44-67
42. Bruzzone, S., De Flora, A., Usai, C., Graeff, R., and Lee, H. C. (2003) Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated proliferation of human peripheral blood mononuclear cells. Biochem. J. 375, 395-403
43. Zocchi, E., Daga, A., Usai, C., Franco, L., Guida, L., Bruzzone, S., Costa, A., Marchetti, C., and De Flora, A. (1998) Expression of CD38 increases intracellular calcium concentration and reduces doubling time in HeLa and 3T3 cells. J. Biol. Chem. 273, 8017-8024
44. Vichai, V., and Kirtikara, K. (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112-1116
45. Bruzzone, S., Guida, L., Zocchi, E., Franco, L., and De Flora, A. (2001) Connexin 43 hemichannels mediate Ca2-regulated transmembrane NAD fluxes in intact cells. FASEB J. 15, 10-12
46. Loewenstein, W. R. (1981) Junctional intercellular communication. The cell-to-cell membrane channel. Physiol. Rev. 61, 829-913
47. Braet, K., Vandamme, W., Martin, P. E., Evans, W. H., and Leybaert, L. (2003) Photoliberating inositol-1,4,5-trisphosphate triggers ATP release that is blocked by the connexin mimetic peptide gap. Cell Calcium 33, 37-48
48. Zocchi, E., Franco, L., Guida, L., Benatti, U., Bargellesi, A., Malavasi, F., Lee, H. C., and De Flora, A. (1993) A single protein immunologically identified as CD38 displays NAD/glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem. Biophys. Res. Commun. 196, 1459-1465
49. Goding, J. W., Terkeltaub, R., Maurice, M., Deterre, P., Sali, A., Belli, S. I. (1998) Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells. Structure and function of the PC-1 family. Immunol. Rev. 161, 11-26
50. Resta, R., Yamashita, Y., and Thompson, L. F. (1998) Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 161, 95-109
51. Colgan, S. P., Eltzschig, H. K., Eckle, T., and Thompson, L. F. (2006) Phys- iological roles for ecto-5-nucleotidase (CD73). Purinergic Signal. 2, 351-360
52. Ferrero, E., and Malavasi, F. (1999) The metamorphosis of a molecule. From soluble enzyme to the leukocyte receptor CD38. J. Leukoc. Biol. 65, 151-161
53. Beavis, P. A., Stagg, J., Darcy, P. K., and Smyth, M. J. (2012) CD73. A potent suppressor of antitumor immune responses. Trends Immunol. 33, 231-237
54. Ujházy, P., Klobusická, M., Babusíková, O., Strausbauch, P., Mihich, E., and Ehrke, M. J. (1994) Ecto-5-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int. J. Cancer 59, 83-93
55. Salmi, M., and Jalkanen, S. (2011) Homing-associated molecules CD73 and VAP-1 as targets to prevent harmful inflammations and cancer spread. FEBS Lett. 585, 1543-1550
56. Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., and Smith, M. J. (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. U.S.A. 107, 1547-1552
57. Zhang, B. (2010) CD73. A novel target for cancer immunotherapy. Cancer Res. 70, 6407-6411
58. Zhang, B. (2012) CD73 promotes tumor growth and metastasis. Oncoimmunology 1, 67-70
59. Zhou, X., Zhi, X., Zhou, P., Chen, S., Zhao, F., Shao, Z., Ou, Z., and Yin, L. (2007) Effects of ecto-5-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol. Rep. 17, 1341-1346
60. Forte, G., Sorrentino, R., Montinaro, A., Luciano, A., Adcock, I. M., Maiolino, P., Arra, C., Cicala, C., Pinto, A., and Morello, S. (2012) Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J. Immunol. 189, 2226-2233